California prescription drug transparency efforts face new scrutiny over pharmaceutical marketing, patient advocacy funding, PBM pricing practices and insulin costs.

A 5% Treasury yield raises the bar for every dividend stock in a retirement portfolio, but four large-cap payers in real ...

Wall Street expects an even bigger rebound for this beaten-down biotech stock.

A new analysis found that one approach may outperform the other when it comes to minimizing the patient's risk of major ...

Pfizer has a compelling risk-reward profile despite near-term COVID normalization and patent expiry headwinds. Find out why ...

Laura Schober is a writer and editor specializing in health, food, wellness, beauty, and lifestyle content. Laura is also a seasoned communications professional who has previously worked in the ...

Kirstyn Hill has worked as a clinical pediatric and women’s health pharmacist since 2020. She was driven to work with a patient population that is not often able to easily speak up for themselves and ...